ArticleInternational microbiology : the official journal of the Spanish Society for Microbiology2025
Alkanna tinctoria extract-mediated biomass synthesis of Ag-ZnO nanoparticles: characterization, antimicrobial and antibiofilm activities.
Article in International microbiology : the official journal of the Spanish Society for Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To combat the issue of pathogenic infections, the current work successfully synthesized a nanocomposite, which is based on the aqueous extract of Alkanna tinctoria (ATE) and silver-zinc oxide nanoparticles (ATE@Ag-ZnO NPs), using a green technique. Analytical methods were used to characterize the synthesized nanocomposite to verify its size, shape, distribution, surface charge, and crystallinity. The resulting nanocomposite created permanent colloidal nano-solutions, demonstrated excellent dispersion, and appeared at the nanoscale. The antimicrobial, antifungal, and antibiofilm characteristics of the ATE@Ag-ZnO nanocomposite were assessed. For every studied microbial strain, the ATE@Ag-ZnO nanocomposite's minimum inhibitory concentration (MIC) was determined. The encouraging findings showed that the MIC range of ATE@Ag-ZnO against all strains was 250-31.25 µg/mL. It demonstrated promise against S. epidermidis and A. calcoaceticus, with a MIC of 31.25 µg/mL. Furthermore, with inhibition zones of 22.0, 20.0, and 15.0 mm, respectively, the ATE@Ag-ZnO nanocomposite demonstrated antibacterial efficacy against gram-positive bacteria A. calcoaceticus, S. epidermidis, and C. tropicalis at 250 µg/mL. The highest percentage of inhibition (91.44%) was seen in S. aureus treated with 250 µg/mL ATE@Ag-ZnO nanocomposite, followed by A. calcoaceticus (68.83%) and C. albicans (64.81%). In conclusion, we successfully created the green synthesized ATE@Ag-ZnO nanocomposite, which demonstrated promising antibacterial, antifungal, and antibiofilm agents against some pathogenic microbes.
Indexed as
Identifiers
41205019What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.